Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer

Head and Neck

Volumn 35, Issue 11, 2013, Pages 1652-1656

  Chen, Allen M ^a   Zahra, Talia ^a   Daly, Megan E ^a   Farwell, D Gregory ^a   Luu, Quang ^a   Gandour Edwards, Regina ^a   Vaughan, Andrew T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

head and neck cancer; human papillomavirus; radiation therapy; radiosensitivity; squamous cell carcinoma

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; WART VIRUS;

HEAD AND NECK CANCER; HUMAN PAPILLOMAVIRUS; RADIATION THERAPY; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84886432461     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23209     Document Type: Article

References (20)

1. Gillison ML, D'Souza G, Westra WH, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
2. Braakhuis BJ, Snijders PJ, Keune WH, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2005; 96: 998-1006.
3. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
4. Singhi AD, Westra WH,. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116: 2166-2173.
5. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 547-581.
6. Cox JD, Stetz J, Pajak TF,. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
7. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
8. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
9. Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharygneal squamous cell carcinoma dependent on the treatment modality? Int J Cancer 2010; 126: 1256-1262.
10. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
11. Lassen P, Eriksen JG, Hamilton S, et al. Effect of HPV-associated p16 expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-1998.
12. Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6 & 7 trial. Radiother Oncol 2011; 100: 49-55.
13. Pang E, Delic NC, Hong A, et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6*I. Int J Radiat Oncol Biol Phys 2011; 79: 860-865.
14. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 1137-1146.
15. Gupta AK, Lee JH, Wilke WW, et al. Radiation response in two HPV-infected head and neck cancer cell lines in comparison to non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 2009; 74: 928-933.
16. Klussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharygneal carcinoma and their prognostic implications. Clin Cancer Res 2009; 15: 1179-1786.
17. Braakhuis BJ, Snijders PJ, Keune WH, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2005; 96: 998-1006.
18. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636.
19. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, bcl-xL, and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
20. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastasis and tumor recurrence. Clin Cancer Res 2010; 16: 1226-1235.